Document Detail


The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia.
MedLine Citation:
PMID:  23049296     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall survival, lower rates or short complete remission and extramedullary invasion but the results are controversial. The importance of validating new prognostic parameters in acute leukemias was the reason to investigate the CD56 expression in blast cells of patients with acute myeloid leukemia.
METHODS: A cohort of 48 patients treated at Hospital de Clinicas de Porto Alegre and diagnosed with acute myeloid leukemia as classified by the French-American-British group (FAB) criteria using cell morphology, cytochemistry and flow cytometry were evaluated.
RESULTS: Eight cases (16.7%) were CD56 positive without correlation to age or gender. The highest incidence of CD56 positivity was in FAB subtypes M4 and M5. The death rate during induction was not significantly different between patients with and without CD56 expression (62.5% vs. 27.5%; p-value = 0.097). However, patients that expressed CD56 had significantly lower overall survival than those who did not (mean 4.0 months vs. 14.5 months; p-value = 0.03).
CONCLUSIONS: The data suggest that expression of CD56 in acute myeloid leukemia may be indicative of poor prognosis because it is associated with a shorter overall survival. The death rate during induction was not significantly different despite an apparent difference in proportions between groups.
Authors:
Ana Paula Alegretti; Christina Matzenbacher Bittar; Rosane Bittencourt; Amanda Kirchner Piccoli; Laiana Schneider; Lúcia Mariano Silla; Suzane Dal Bó; Ricardo Machado Xavier
Related Documents :
23293426 - Head and neck contrast-enhanced ct for identification of internal carotid artery stenos...
1766446 - Aaem case report #23: acute paralytic poliomyelitis.
23647296 - Radiotherapy in the management of prostate cancer after radical prostatectomy.
23544356 - Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofracti...
17141976 - Reduced-intensity conditioning regimen using low-dose total body irradiation before all...
7902316 - Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a stud...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Revista brasileira de hematologia e hemoterapia     Volume:  33     ISSN:  1806-0870     ISO Abbreviation:  Rev Bras Hematol Hemoter     Publication Date:  2011  
Date Detail:
Created Date:  2012-10-10     Completed Date:  2012-10-10     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101220159     Medline TA:  Rev Bras Hematol Hemoter     Country:  Brazil    
Other Details:
Languages:  eng     Pagination:  202-6     Citation Subset:  -    
Affiliation:
Clinical Pathology Service, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul - UFRGS, Porto Alegre, RS, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hematological and immunological effects of stress of air traffic controllers in northeastern Brazil.
Next Document:  Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia tr...